Activin and estrogen crosstalk regulates transcription in human breast cancer cells

Endocrine-Related Cancer

Volumn 14, Issue 3, 2007, Pages 679-689

  Burdette, Joanna E ^a,b   Woodruff, Teresa K ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN; CAGA PROTEIN; ESTROGEN; ESTROGEN RECEPTOR ALPHA; LIGAND; LUCIFERASE; MESSENGER RNA; MYELOPID; PLASMINOGEN ACTIVATOR INHIBITOR 1; SMAD PROTEIN; SMAD3 PROTEIN; TREFOIL PEPTIDE;

ARTICLE; BREAST CANCER; BREAST CELL; CANCER CELL; CANCER GROWTH; CELL CYCLE ARREST; CELL GROWTH; CONTROLLED STUDY; ESTROGEN RESPONSIVE ELEMENT; GENE EXPRESSION; GENE OVEREXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; PROMOTER REGION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ACTIVIN RECEPTORS, TYPE I; ACTIVINS; BREAST NEOPLASMS; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; ESTROGENS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; HUMANS; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECEPTOR CROSS-TALK; RESPONSE ELEMENTS; SMAD3 PROTEIN; TRANSCRIPTION, GENETIC; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 35948947911     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/ERC-07-0054     Document Type: Article

References (48)

1. Anderson E 2002 The role of oestrogen and progesterone receptors in human mammary development and tumorigenesis. Breast Cancer Research 4 197-201.
2. Ariazi EA, Ariazi JL, Cordera F & Jordan VC 2006 Estrogen receptors as therapeutic targets in breast cancer. Current Topics in Medicinal Chemistry 6 181-202.
3. Arteaga CL, Koli KM, Dugger TC & Clarke R 1999 Reversal of tamoxifen resistance of human breast carcinomas in vivo by neutralizing antibodies to transforming growth factor-beta. Journal of National Cancer Institute 91 46-53.
4. Brandt S, Kopp A, Grage B & Knabbe C 2003 Effects of tamoxifen on transcriptional level of transforming growth factor beta (TGF-beta) isoforms 1 and 2 in tumor tissue during primary treatment of patients with breast cancer. Anticancer Research 23 223-229.
5. Buck MB, Pfizenmaier K & Knabbe C 2004 Antiestrogens induce growth inhibition by sequential activation of p38 mitogen-activated protein kinase and transforming growth factor-beta pathways in human breast cancer cells. Molecular Endocrinology 18 1643-1657.
6. Burdette JE, Jeruss JS, Kurley SJ, Lee EJ & Woodruff TK 2005 Activin A mediates growth inhibition and cell cycle arrest through Smads in human breast cancer cells. Cancer Research 65 7968-7975.
7. Bussmann UA, Lanuza GM & Bussmann LE 2004 Activin and follistatin in rat mammary gland. Molecular and Cellular Endocrinology 221 9-19.
8. Clarke R, Liu MC, Bouker KB, Gu Z, Lee RY, Zhu Y, Skaar TC, Gomez B, O'Brien K, Wang Y et al. 2003 Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 22 7316-7339.
9. Cocolakis E, Lemay S, Ali S & Lebrun JJ 2001 The p38 MAPK pathway is required for cell growth inhibition of human breast cancer cells in response to activin. Journal of Biological Chemistry 276 18430-18436.
10. Corte MD, Verez P, Rodriguez JC, Roibas A, Dominguez ML, Lamelas ML, Vazquez J, Vazquez J, Garcia Muniz JL, Allende MT et al. 2005 Tissue-type plasminogen activator (tPA) in breast cancer: relationship with clinicopathological parameters and prognostic significance. Breast Cancer Research and Treatment 90 33-40.
11. Dennler S, Itoh S, Vivien D, ten Dijke P, Huet S & Gauthier JM 1998 Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO Journal 17 3091-3100.
12. Di Loreto C, Reis FM, Cataldi P, Zuiani C, Luisi S, Beltrami CA & Petraglia F 1999 Human mammary gland and breast carcinoma contain immunoreactive inhibin/activin subunits: evidence for a secretion into cystic fluid. European Journal of Endocrinology 141 190-194.
13. Frasor J, Danes JM, Komm B, Chang KC, Lyttle CR & Katzenellenbogen BS 2003 Profiling of estrogen up-and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 144 4562-4574.
14. Hayes SA, Zarnegar M, Sharma M, Yang F, Peehl DM, ten Dijke P & Sun Z 2001 SMAD3 represses androgen receptor-mediated transcription. Cancer Research 61 2112-2118.
15. Helms MW, Packeisen J, August C, Schittek B, Boecker W, Brandt BH & Buerger H 2005 First evidence supporting a potential role for the BMP/SMAD pathway in the progression of oestrogen receptor-positive breast cancer. Journal of Pathology 206 366-376.
16. Herman ME & Katzenellenbogen BS 1996 Response-specific antiestrogen resistance in a newly characterized MCF-7 human breast cancer cell line resulting from long-term exposure to trans-hydroxytamoxifen. Journal of Steroid Biochemistry and Molecular Biology 59 121-134.
17. Imamov O, Shim GJ, Warner M & Gustafsson JA 2005 Estrogen receptor beta in health and disease. Biology of Reproduction 73 866-871.
18. Jeruss JS, Sturgis CD, Rademaker AW & Woodruff TK 2003 Down-regulation of activin, activin receptors, and Smads in high-grade breast cancer. Cancer Research 63 3783-3790.
19. Kalkhoven E, Roelen BA, de Winter JP, Mummery CL, van den Eijnden-van Raaij AJ, van der Saag PT & van der Burg B 1995 Resistance to transforming growth factor beta and activin due to reduced receptor expression in human breast tumor cell lines. Cell Growth and Differentiation 6 1151-1161.
20. Katzenellenbogen BS & Frasor J 2004 Therapeutic targeting in the estrogen receptor hormonal pathway. Seminars in Oncology 31 28-38.
21. Kenny HA, Bernard DJ, Horton TH & Woodruff TK 2002 Photoperiod-dependent regulation of inhibin in Siberian hamsters: I. Ovarian inhibin production and secretion. Journal of Endocrinology 174 71-83.
22. Knabbe C, Lippman ME, Wakefield LM, Flanders KC, Kasid A, Derynck R & Dickson RB 1987 Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell 48 417-428.
23. Landis MD, Seachrist DD, Montanez-Wiscovich ME, Danielpour D & Keri RA 2005 Gene expression profiling of cancer progression reveals intrinsic regulation of transforming growth factor-beta signaling in ErbB2/Neu-induced tumors from transgenic mice. Oncogene 24 5173-5190.
24. Leto G, Incorvaia L, Badalamenti G, Tumminello FM, Gebbia N, Flandina C, Crescimanno M & Rini G 2006 Activin A circulating levels in patients with bone metastasis from breast or prostate cancer. Clinical & Experimental Metastasis 23 117-122.
25. Levenson AS, Svoboda KM, Kwaan HC & Jordan VC 1998a Agonist activity of antiestrogen-receptor complexes to regulate urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) endogenous gene expression in breast cancer cells. Cancer Letters 125 215-220.
26. Levenson AS, Kwaan HC, Svoboda KM, Weiss IM, Sakurai S & Jordan VC 19986 Oestradiol regulation of the components of the plasminogen-plasmin system in MDA-MB-231 human breast cancer cells stably expressing the oestrogen receptor. British Journal of Cancer 78 88-95.
27. Li Q, Wu L, Oelschlager DK, Wan M, Stockard CR, Grizzle WE, Wang N, Chen H, Sun Y & Cao X 2005 Smad4 inhibits tumor growth by inducing apoptosis in estrogen receptor-alpha-positive breast cancer cells. Journal of Biological Chemistry 280 27022-27028.
28. Liu QY, Niranjan B, Gomes P, Gomm JJ, Davies D, Coombes RC & Buluwela L 1996 Inhibitory effects of activin on the growth and morpholgenesis of primary and transformed mammary epithelial cells. Cancer Research 56 1155-1163.
29. Malek D, Gust R & Kleuser B 2006 17-Beta-estradiol inhibits transforming-growth-factor-beta-induced MCF-7 cell migration by Smad3-repression. European Journal of Pharmacology 534 39-47.
30. Malet C, Fibleuil F, Mestayer C, Mowszowicz I & Kuttenn F 2001 Estrogen and antiestrogen actions on transforming growth factorbeta (TGFbeta) in normal human breast epithelial (HBE) cells. Molecular and Cellular Endocrinology 174 21-30.
31. Martini PG & Katzenellenbogen BS 2003 Modulation of estrogen receptor activity by selective coregulators. Journal of Steroid Biochemistry and Molecular Biology 85 117-122.
32. Matsuda T, Yamamoto T, Muraguchi A & Saatcioglu F 2001 Cross-talk between transforming growth factor-beta and estrogen receptor signaling through Smad3. Journal of Biological Chemistry 276 42908-42914.
33. Matzuk MM, Kumar TR, Vassalli A, Bickenbach JR, Roop DR, Jaenisch R & Bradley A 1995 Functional analysis of activins during mammalian development. Nature 374 354-356.
34. Mylonas I, Jeschke U, Shabani N, Kuhn C, Friese K & Gerber B 2005 Inhibin/activin subunits (inhibin-alpha, betaA, and betaB) are differentially expressed in human breast cancer and their metastasis. Oncology Reports 13 81-88.
35. Nicholson RI, McClelland RA, Robertson JF & Gee JM 1999 Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. Endocrine-Related Cancer 6 373-387.
36. Nicholson RI, Hutcheson IR, Britton D, Knowlden JM, Jones HE, Harper ME, Hiscox SE, Barrow D & Gee JM 2005 Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies. Journal of Steroid Biochemistry and Molecular Biology 93 257-262.
37. Paez-Pereda M, Giacomini D, Refojo D, Nagashima AC, Hopfner U, Grubler Y, Chervin A, Goldberg V, Goya R, Hentges ST et al. 2003 Involvement of bone morphogenetic protein 4 (BMP-4) in pituitary prolactinoma pathogenesis through a Smad/estrogen receptor crosstalk. PNAS 100 1034-1039.
38. Pangas SA & Woodruff TK 2002 Production and purification of recombinant human inhibin and activin. Journal of Endocrinology 172 199-210.
39. Reis FM, Cobellis L, Tameirao LC, Anania G, Luisi S, Silva IS, Gioffre W, Di Blasio AM & Petraglia F 2002 Serum and tissue expression of activin a in postmenopausal women with breast cancer. Journal of Clinical Endocrinology and Metabolism 87 2277-2282.
40. Reis FM, Luisi S, Carneiro MM, Cobellis L, Federico M, Camargos AF & Petraglia F 2004 Activin, inhibin and the human breast. Molecular and Cellular Endocrinology 225 77-82.
41. Robinson GW & Hennighausen L 1997 Inhibins and activins regulate mammary epithelial cell differentiation through mesenchymal-epithelial interactions. Development 124 2701-2708.
42. Sabnis GJ, Jelovac D, Long B & Brodie A 2005 The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation. Cancer Research 65 3903-3910.
43. Smith CL & O'Malley BW 2004 Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocrine Reviews 25 45-71.
44. Tong D, Czerwenka K, Sedlak J, Schneeberger C, Schiebel I, Concin N, Leodolter S & Zeillinger R 1999 Association of in vitro invasiveness and gene expression of estrogen receptor, progesterone receptor, pS2 and plasminogen activator inhibitor-1 in human breast cancer cell lines. Breast Cancer Research and Treatment 56 91-97.
45. Wu L, Wu Y, Gathings B, Wan M, Li X, Grizzle W, Liu Z, Lu C, Mao Z & Cao X 2003 Smad4 as a transcription corepressor for estrogen receptor alpha. Journal of Biological Chemistry 278 15192-15200.
46. Yamamoto T, Saatcioglu F & Matsuda T 2002 Cross-talk between bone morphogenic proteins and estrogen receptor signaling. Endocrinology 143 2635-2642.
47. Yanagisawa J, Yanagi Y, Masuhiro Y, Suzawa M, Watanabe M, Kashiwagi K, Toriyabe T, Kawabata M, Miyazono K & Kato S 1999 Convergence of transforming growth factor-beta and vitamin D signaling pathways on SMAD transcriptional coactivators. Science 283 1317-1321.
48. Ying SY & Zhang Z 1996 Expression and localization of inhibin/activin subunits and activin receptors in MCF-7 cells, a human breast cancer cell line. Breast Cancer Research and Treatment 37 151-160.